Top Markets
Coin of the day
INOVIQ Ltd INOVIQ Ltd

INOVIQ Ltd

IIQ
Rank in Stocks #29964
INOVIQ Ltd specializes in the research, development, and commercialization of... INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Share Price
$0.13400411
Market Cap
$18.86M
Change (1 day)
2.70%
Change (1 year)
-48.10%
Country
AU
Trade INOVIQ Ltd (IIQ)

Category

Revenue for INOVIQ Ltd (IIQ)
Revenue in Aug 2026 TTM: 0
According to INOVIQ Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for INOVIQ Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$46.34B -
US
$25.11B -
US
- -
CN
$2.71B -
US
$4.55B -
US